Ocumension Therapeutics (HKG:1477) expects revenue to come between 408 million yuan and 420 million yuan for the year ended Dec. 31, up to 70.5% higher compared with the 246.4 million yuan in the previous year, according to a Wednesday filing with the Hong Kong bourse.
The company attributed the increase in revenue to an increase in sales of its corr lle products' among other factors.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。